Compass Pathways plc is a clinical-stage mental health care company focused on developing innovative treatments for patients with treatment-resistant depression and other mental health disorders. Founded in 2016 and headquartered in London, the company is driven by a mission to address unmet needs in psychiatric care through the therapeutic use of psilocybin, the active compound found in certain species of mushrooms. Compass Pathways is listed on the Nasdaq under the ticker symbol CMPS and operates as a pioneering force in the emerging field of psychedelic-assisted therapies.
The company’s lead product candidate is COMP360, a proprietary formulation of synthetic psilocybin designed for use in conjunction with psychological support. COMP360 has completed a Phase IIb clinical trial in patients with treatment-resistant depression, demonstrating promising efficacy and safety results compared to placebo. Compass is advancing COMP360 through regulatory pathways, aiming to secure marketing approval by working closely with agencies such as the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). Alongside its lead program, the company continues to explore additional indications and optimize dosing protocols and therapeutic approaches.
Compass Pathways’ research and development activities span multiple geographies, with clinical trial sites across the United States, Europe and Canada. The company has established strategic collaborations with leading academic centers and research institutions to further its understanding of psilocybin’s mechanism of action and to refine best practices for integration of psychedelic therapies into mainstream clinical settings. These partnerships extend to clinical psychologists, psychiatrists and other mental health professionals who deliver the therapeutic care component of the treatment regimen.
Leadership at Compass Pathways combines expertise in biotechnology, pharmaceuticals and mental health advocacy. George Goldsmith, the company’s founder and Chief Executive Officer, has led growth efforts and guided the strategic vision since inception. The executive team includes seasoned professionals in clinical development, regulatory affairs and commercial strategy, supported by a Board of Directors with deep experience in life sciences and public markets. Together, this leadership group is committed to advancing psilocybin therapy as a safe, scalable and evidence-based option for those suffering from severe psychiatric conditions.
AI Generated. May Contain Errors.
Free CMPS Stock Alerts